补肺化瘀汤联合吉非替尼对非小细胞肺癌患者的应用效果分析  

Analysis of Gefitinib in Patients with Non-Small Cell Lung Cancer

作　　者：贾盛豪 JIA Shenghao(People's Hospital of Yancheng District,Luohe,462000)

机构地区：[1]河南省漯河市郾城区人民医院,462000

出　　处：《实用癌症杂志》2024年第11期1874-1876,共3页The Practical Journal of Cancer

摘　　要：目的探讨补肺化瘀汤联合吉非替尼治疗非小细胞肺癌(NSCLC)的临床效果。方法选取82例NSCLC患者,随机分为2组,各41例。对照组口服吉非替尼治疗,观察组加用补肺化瘀汤治疗,持续2个周期。比较两组临床疗效、免疫功能、中医证候评分及不良反应。结果观察组疾病控制率较对照组高,治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组,有统计学差异(P<0.05);观察组治疗后咳嗽、气喘、神疲乏力、少气懒言评分低于对照组,有统计学差异(P<0.05);两组不良反应相比,无统计学差异(P>0.05)。结论补肺化瘀汤联合吉非替尼可提高NSCLC控制效果,纠正免疫紊乱,降低中医证候评分,加快血清VEGF、MMP-9复常,安全可靠。Objective To investigate the clinical effect of Bufei Huayu Decoction combined with gefitinib in the treatment of non-small cell lung cancer(NSCLC).Methods A total of 82 patients with NSCLC were randomly divided into 2 groups,with 41 cases in each group.The control group was treated with gefitinib orally,and the observation group was treated with Bufei Huayu decoction for 2 cycles.The clinical efficacy,immune function,TCM syndrome score and adverse reactions were compared between the 2 groups.Results The disease control rate of the observation group was higher than that of the control group.After treatment,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)were higher than the control group,and CD8^(+)were lower than the control group,with statistical difference(P<0.05).After treatment,the scores of cough,asthma,fatigue,low qi and lazy talk in the observation group were lower than those in the control group,with statistical differences(P<0.05);There was no significant difference in adverse reactions between the 2 groups(P>0.05).Conclusion Bufei Huayu Decoction combined with gefitinib can improve the control effect of NSCLC,correct immune disorders,reduce TCM syndrome score,accelerate the recovery of serum VEGF and MMP-9,which is safe and reliable.

关 键 词：非小细胞肺癌 补肺化瘀汤 吉非替尼 免疫功能 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]